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Abstract
Development of magnetic resonance imaging (MRI) contrast agents that can be readily applied for imaging of biological
tissues under clinical settings is a challenging task. This is predominantly due to the expectation of an ideal MR agent being
able to be synthesized in large quantities, possessing longer shelf life, reasonable biocompatibility, tolerance against its
aggregation in biological fluids, and high relaxivity, resulting in better contrast during biological imaging. Although a
repertoire of reports address various aforementioned issues, the previously reported results are far from optimal, which
necessitates further efforts in this area. In this study, we demonstrate facile large-scale synthesis of sub-100 nm quasi-cubic
magnetite and magnetite/silica core-shell (Mag@SiO2) nanoparticles and their applicability as a biocompatible T2 contrast
agent for MRI of biological tissues. Our study suggests that silica-coated magnetite nanoparticles reported in this study can
potentially act as improved MR contrast agents by addressing a number of aforementioned issues, including longer shelf life
and stability in biological fluids. Additionally, our in vitro and in vivo studies clearly demonstrate the importance of silica
coating towards improved applicability of T2 contrast agents for cancer imaging.
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Introduction
Interest in magnetic nanomaterials has persisted over the last
few decades primarily due to their applications across many fields
such as magnetic data recording, sensing, catalysis and biomed-
icine [1–5]. Magnetic nanomaterials have attracted particular
attention in biomedicine due to their great potential in improving
the currently available disease diagnostics, prevention, and
therapeutic approaches [6]. For instance, the potential of magnetic
nanoparticles to precisely deliver highly biotoxic drugs to specific
locations in the body [6], as well as their use as highly specialized
bio-probes for diagnostic imaging has been demonstrated by
attaching biomolecular markers to their surface [1,7]. With these
developments, there is an increasing demand to develop
biocompatible magnetic nanomaterials with ultra-sensitive imag-
ing capabilities in order that they can be used for a wide range of in
vivo medical imaging applications.
Magnetic resonance imaging (MRI) is regarded as a powerful
imaging tool because of its high spatial resolution capability, non-
invasive nature and its capability to avoid ionizing radiation in
contrast to nuclear imaging techniques such as positron emission
tomography (PET) [8–10]. Briefly, MRI operates by taking
advantage of the exceptionally small magnetic moment inherent
on each proton that, under the presence of a large magnetic field,
produces an effect measurable as a signal on the MR image. The
signals produced via T1 relaxation (spin-lattice relaxation) or T2
relaxation (spin-spin relaxation) depends on the sequence
parameters programmed to acquire the MR image. Overall, T1
weighted and T2 weighted imaging provide different contrasting
effects between fluid and body tissue. For instance T1 weighted
images show fluid as dark, water-based tissues as grey and fat-
based tissues as bright, thereby very clearly showing the
boundaries between different tissues. Conversely, on T2 weighted
images, fluid appears bright and water- and fat-based tissues
appear grey. The use of contrast agents greatly improves the
specificity and sensitivity of MRI by shortening either T1 or T2
relaxation of the water protons adjacent to them, thus providing
more detailed information about pathology. Gadolinium-based T1
contrast agents are most commonly used in MRI, however
growing concerns over the safety of gadolinium-based contrasts
have lead to a major shift towards iron oxide based T2 contrast
agents that are deemed to be relatively biologically safe [11–13].
Although, iron oxide based contrast agents have been clinically
approved for MRI, their use has been predominantly restricted to
liver/spleen imaging (AMI-25 FeridexH - not in use anymore) and
the gastrointestinal lumen imaging (LumiremH/GastromarkH).
This limitation is primarily due to the larger size of the iron oxide
particles involved in these agents, which are either taken up
immediately by the reticuloendothelium system after intravenous
administration (FeridexH), or are administered orally (LumiremH/
GastromarkH). Therefore, there is a clinical urgency to develop
commercially viable and biologically safe contrast agents that can
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Moreover, there have been numerous reports on different
synthesis routes to magnetic nanoparticles-based contrast agents,
including biologically synthesized magnetic nanoparticles [17–18],
magnetic nanoparticles with dendrimer cores [19], superpara-
magnetic liposomes [20], lipid-based MR contrast agents [21],
metal-doped magnetic nanoparticles [22–25], CoFe2O4@SiO2
particles with fluorescent dyes incorporated [26], and magnetic
nanoparticles for both imaging and therapeutic applications [27].
Additionally, in the pre-clinical setting, the trend over the last few
years has been towards the development of small (sub-100 nm)
iron oxide nanoparticles [24,28–31]. The previous studies suggest
that to shift from sub-micron iron oxide particles to their
nanoparticulate form in the clinical environment, the challenges
that need to be overcome include their low chemical and
biological stability, small shelf life, inherent low-to-high cytotox-
icity, and low magnetization associated with the iron oxide
nanoparticles, which has although been addressed by few recent
studies to some extent, it still requires additional efforts in this area
[32–34]. This is predominantly because the aforementioned
properties of MR contrast agents can strongly depend on their
synthesis route.
In this manuscript, we address most of the aforementioned
issues by demonstrating the development of a T2-weighted, iron
oxide-based MRI contrast agent with reasonably low cytotoxicity,
high relaxivity, and particularly notable high stability that can be
stored at room temperature for more than 6 months without any
visible aggregation. The chemical stability of these nanoparticles is
achieved by coating them with an inorganic silica (SiO2) layer,
leading to Mag@SiO2 core-shell nanoparticles. The resulting
nanoparticles were analyzed by a superconducting quantum
interference measurement device (SQUID), high resolution
transmission electron microscopy (HRTEM), X-ray diffraction
(XRD) and a 3 Tesla clinical MRI scanner. Our in vitro studies
indicate that coating with SiO2 renders these nanoparticles
biocompatible and they are actively taken up by prostate cancer
cells under in vitro conditions. Our preliminary in vivo studies with a
breast tumor animal model further suggests their potential utility
as good MRI contrast agents for tumor imaging.
Results and Discussion
Figure 1A shows the TEM image of the magnetic (Mag)
nanoparticles, which indicates that the as-synthesized Mag
nanoparticles prepared by our synthesis route were quasi-cubic
in morphology with good monodispersity and an average size of
4065 nm. Notably, using our approach, large scale synthesis of
Mag nanoparticles could be achieved (at least up to 10 g particles
per batch) without compromising the nanoparticle shape or
monodispersity. From the higher magnification TEM image, these
Mag nanoparticles were found to have spherical edges, and it
appears as if these nanoparticles consist of several smaller spherical
particles that assemble together giving rise to quasi-cubic
structures (inset Figure 1A). It is important to note that under
room temperature storage conditions, pristine Mag nanoparticles
lose their quasi-cubic morphology and turn spherical after two
weeks of synthesis. The shelf life of commercially available MRI
contrast agents is in fact one of the major limitations associated
with clinical applicability of such materials. SiO2 shell coating has
been previously demonstrated to provide biocompatibility, particle
stability as well as a facile surface for further biofunctionalisation in
different nanomaterials [27–29]. Therefore, to provide chemical
stability to magnetic nanoparticles, a silica shell was grown around
quasi-cubic Mag particles (within 3 days of their synthesis), thereby
producing Mag@SiO2 core-shell nanoparticles (Figure 1B). The
controlled silica coating of Mag nanoparticles led to formation of
Mag@SiO2 core-shell structures with a ca. 2062 nm silica shell
around 4065 nm quasi-cubic Mag nanoparticles (Figure 1B and
inset). Large area TEM analysis of Mag@SiO2 core-shell
structures indicated that most of the Mag nanoparticles retained
their quasi-cubic morphology after silica coating, and more than
ca. 75% of particles in the sample were found to be individually
coated with a silica shell. However, less than ca. 25% of structures
consisted of either two or three or no Mag particles within the
silica shell. Notably, this type of particle distribution is typical of a
chemical synthesis route, which is not necessarily always explicitly
acknowledged in the prevailing literature. Additionally, we
observed that after coating Mag nanoparticles with silica, the
Mag@SiO2 particles remain stable in phosphate buffer saline
(PBS) solution for at least up to 1 mg/mL concentration, as well as
in the readily-dispersible powder form for at least up to 6 months.
The TEM image shown in Figure 1B was acquired after 6 months
of storage of Mag@SiO2 nanoparticles at room temperature and
was similar to those imaged immediately after synthesis. This
suggests that a silica coating over Mag nanoparticles can
significantly improve their stability for long-term storage condi-
tions, thus retaining their magnetic properties by improving their
shelf life. This is one of the crucial parameters for developing
Figure 1. TEM images of (A) Mag and (B) Mag@SiO2 core-shell nanoparticles. Insets show the respective higher resolution TEM images.
doi:10.1371/journal.pone.0021857.g001
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Figure 2 shows the XRD patterns of Mag and Mag@SiO2
nanoparticles. The XRD pattern obtained from quasi-cubic Mag
nanoparticles (curve 1) could be indexed based on standard
diffraction pattern typically arising from magnetite (Fe3O4) with
major peaks indexed (JCPDS file No 75–0449). After silica
coating, most of the diffraction peaks arising from Mag
nanoparticles could still be detected. However interestingly, after
silica coating, an additional peak at ca. 29.3 ˚ 2h was observed that
could be assigned to the (220) plane of a FeSi2 phase (curve 2)
(JSPDS file no. 73-0963). The mixed Fe-Si phase is most likely
formed at the interface of silica and magnetite during core-shell
synthesis of Mag@SiO2 nanoparticles.
High saturation magnetization of MR contrast agents is an
important requirement for the magnetic nanoparticles to be used
for MRI application. The magnetic hysteresis curve of Mag@-
SiO2 nanoparticles obtained by SQUID measurement is shown in
Figure 3, which was found to have no coercive fields, thus
confirming their superparamagnetic nature. Mag@SiO2 nano-
particles were found to possess a relatively high mass magnetiza-
tion value of 74.4 emu/g, which is comparable to the previously
reported mass magnetisation values of 72.9 emu/g for commer-
cially available Resovist iron oxide particles [35].
The Mag and Mag@SiO2 synthesized in this study were further
tested for their ability to be internalised by human prostate cancer
PC3 cells (Figure 4). When subjected to cell uptake studies for
24 h, 50 mg/mL Mag@SiO2 nanoparticles were found to be
uptaken by PC3 prostate cancer cells more efficiently than similar
a concentration of bare Mag nanoparticles (compare Figures 4B
and C). When PC3 cancer cells were exposed to Mag
nanoparticles, we observed that bare Mag nanoparticles without
any SiO2 coating tended to form large aggregates (of dimensions
similar to cell size) in the solution over a 24 h exposure period,
which restricted their ability to be uptaken by PC3 cells
(Figure 4B). As can be inferred from Figure 4B, these large
clusters of bare Mag nanoparticles predominantly attach to the
exterior of the cells, and are difficult to be internalized by PC3
prostate cancer cells. Conversely, after SiO2 coating, Mag@SiO2
nanoparticles remain well-dispersed in the solution even after
24 h, which facilitates their efficient uptake by PC3 cells, as can be
seen from a higher density of Mag@SiO2 nanoparticles inside
PC3 prostate cancer cells (Figure 4C). Our group and others have
previously demonstrated that nanoparticle size and aggregation in
biological media can play a crucial role in cellular uptake
processes, as non-specific uptake of sub-100 nm nanoparticles is
generally observed via endocytosis mechanism of the cells [36–39].
Aggregation of bare (pristine) Mag nanoparticles in biological
media, and avoidance of their aggregation after silica coating
clearly suggests the important role of SiO2 coating, and advantage
of Mag@SiO2 core-shell nanoparticles over bare Mag nanopar-
ticles for biological applications. Based on results from cell uptake
studies, pristine Mag nanoparticles were found to be unsuitable for
biological applications, and therefore only Mag@SiO2 nanopar-
ticles were chosen for further studies regarding their suitability for
MRI applications.
From the cell uptake studies, it is also evident that Mag@SiO2
nanoparticles do not cause any significant change to the
morphology of PC3 prostate cancer cells. Previous studies indicate
that iron oxide nanoparticles are non-toxic at lower concentration,
but can be mildly toxic at higher concentrations [40–41]. Before
exploring Mag@SiO2 nanoparticles for MRI application, bio-
compatibility profile of these particles was assessed by performing
MTS-based in vitro cytotoxicity experiments on PC3 prostate
cancer cells, which is one of the measures of biocompatibility
(Figure 5). It is evident from Figure 5 that Mag@SiO2
nanoparticles did not significantly affect PC3 cell viability for at
least up to 50 mg mL-1 Fe concentrations, at which more than
85% PC3 cells viability was maintained. However further increase
in Mag@SiO2 nanoparticles concentration equivalent to 100 mg
mL
21 Fe resulted in a cell viability loss of ca. 30%. This suggests
that Mag@SiO2 nanoparticles reported in this study may be
suitable for MRI applications within 50 mgm L
21 Fe concentra-
tion range. However, this aspect may require further detailed
investigation, wherein effect of Mag@SiO2 nanoparticles on
cytokine production profile of cells will need to be investigated.
Since magnetic nanomaterials can modulate MR signal
enhancement effects, the capability of Mag@SiO2 nanoparticles
as T2 MR contrast agent was further assessed in terms of their
relaxivity (R2 or relaxation rate, which equals 1/T2 where T2 is
spin-spin relaxation time) on a 3 Tesla clinical MRI scanner at an
echo time (TE) of 10.86 ms. Relaxivity is a measure of the
efficiency of a MR contrast agent to enhance the proton relaxation
and increase the efficiency to which image contrast is produced
during MRI [42]. The relaxivity measurements were performed
both on nanoparticles as suspension in phantoms as well as after
being uptaken by PC3 prostate cancer cells. Mag@SiO2
nanoparticles were found to have a high relaxivity value of
263.23 l/mmol/s in cell free suspensions, and 230.90 l/mmol/s
for Mag@SiO2 nanoparticles within the PC3 cells. High relaxivity
value (that is, better MR contrast) along with high mass
magnetisation value for MRI are important considerations when
developing T2 contrast agents, as the spin-spin relaxation process
of protons in water molecules surrounding the nanoparticles is
facilitated by the large magnitude of magnetic spins in nanopar-
ticles [43–44]. Mag@SiO2 nanoparticles with high mass magne-
tization and high relaxivity values may therefore result in strong
T2-weighted MR signal intensity decrease as measured by MRI
Figure 2. XRD patterns obtained from Mag and Mag@SiO2
nanoparticles. XRD peaks with corresponding Bragg reflections of
magnetite have been indicated. (*) corresponds to the XRD peak arising
from a mixed Fe-Si phase.
doi:10.1371/journal.pone.0021857.g002
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agents, which will facilitate in reducing the overall contrast agent
dose to the patients.
The relaxivity data also suggests a reduction in the relaxivity
value of Mag@SiO2 nanoparticles in PC3 cells after cellular
uptake compared with that in suspension. This finding corrobo-
rates well with previous studies, which showed that the relaxivities
of native iron oxide nanoparticles were higher compared to those
after accumulation in the cells [46–47]. The mechanisms
responsible for this effect have not yet been fully understood,
however it can possibly be attributed to the confinement of
nanoparticles within endosomes of the target cells, which might
cause a build-up of magnetic field inhomogeneities after sub-
cellular compartmentalization, which would conversely be absent
in uniformly distributed nanoparticles in suspensions [48].
Additionally, the different geometrical arrangement of nanopar-
ticles in suspensions and in cells, and possibly antiferromagnetic
coupling as a result of clustering within the sub-cellular
compartments may play some role in reducing relaxivity values
after cellular uptake [28,48]. Notably, in contrast to relaxivity
values of 230–269 l/mmol/s observed for Mag@SiO2 nanopar-
ticles in this study, commercial Resovist based nanoparticles have
been reported with lower values of 151 l/mmol/s [35]. The
observed relaxivity value of Mag@SiO2 nanoparticles prepared in
this study is also relatively higher than those reported for undoped
magnetite particles (218 l/mmol/s) in recent detailed studies [24].
For doped magnetic particles, it has been reported that high
relaxivities of up to 358 l/mmol/s can be achieved by doping
magnetite with Mn (MnFe2O4) [24]. However, potential leaching
of Mn during administration of these MR contrast agents in the
body might pose cytotoxicity issues, and to the best of authors’
knowledge, undoped Mag@SiO2 nanoparticles with such high
relaxivity values have not hitherto been reported.
Furthermore, relaxivity studies as a function of different
concentrations of Fe in Mag@SiO2 nanoparticles, both as a
nanoparticle suspension in phantoms (Figure 6A), and after 24 h
of nanoparticle uptake by PC3 prostate cancer cells (Figure 6B)
revealed that Mag@SiO2 nanoparticles act as outstanding T2-
weighted contrast agents. This is shown by an image darkening
effect, demonstrated by drop in R2 (DR2/R2control) signal intensity
with increasing Fe concentrations. For instance, at 100 mg/mL Fe
concentration, Mag@SiO2 nanoparticles provide a signal en-
hancement of ,90% in comparison to more than 70% signal
enhancement during imaging of PC3 prostate cancer cells. This is
a significant signal enhancement in comparison to most of the
previously reported materials, in which generally only 15–20%
Figure 3. Magnetic hysteresis curve of Mag@SiO2 nanoparticles used for MR imaging of tumor cells and tissues.
doi:10.1371/journal.pone.0021857.g003
Figure 4. Optical microscopy images of PC3 human prostate
cancer cells (control) grown for 24 h (A) in the absence of
nanoparticles, and in the presence of (B) Mag and (C)
Mag@SiO2 nanoparticles followed by three washings with PBS.
doi:10.1371/journal.pone.0021857.g004
Figure 5. Biocompatibility of Mag@SiO2 nanoparticles assess-
ed using MTT assay after their exposure to PC3 cancer cells for
24 h with respect to different Fe concentration in Mag@SiO2
nanoparticles.
doi:10.1371/journal.pone.0021857.g005
Quasi-Cubic Magnetite/Silica for MRI
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e21857signal enhancement has been observed [28]. Such strong MR
signal enhancement is expected from Mag@SiO2 nanoparticles
because of their relatively high relaxivity and saturation magne-
tization values.
In vivo MRI studies in a breast tumor mouse model also
demonstrated T2 signal enhancement at the tumor site by
Mag@SiO2 nanoparticles (Figure 7). The images following in vivo
administration of 10 mg dose of Mag@SiO2 nanoparticles
demonstrate its ability to produce MR enhancement of the tumor
site relative to the body. T2-weighted signal enhancement effects
by the Mag@SiO2 nanoparticles on an MR image are visualised
as darkening or contrast between areas infiltrated with Mag@-
SiO2 nanoparticle and those without nanoparticles. Future studies
on Mag@SiO2 can be tailored for targeted MRI, utilising its
superior magnetic characteristics in the diagnosis of pathologies.
In summary, important considerations for an efficient MRI
contrast agent include smaller particle size, their efficient uptake
by cells, reduced aggregation in biological fluids, improved shelf
life, and improved biocompatibility. A control over all these
parameters will provide an ability to target a range of molecular/
cellular imaging applications without causing acute toxicity to the
normal cells. Particularly for tumor imaging applications, sub-
100 nm particles can provide significant an advantage, as the cut-
off diameter of tumor vessel pores is 400–600 nm [41–43,49–51].
In this study, we have demonstrated a facile, large-scale
synthesis of quasi-cubic magnetite and Mag@SiO2 nanoparticles
of sub-100 nm size. The Mag@SiO2 nanoparticles reported here
have a shelf life of more than 6 months, and they are efficiently
uptaken by the cells without causing significant aggregation or
cellular toxicity. The biological half-life of smaller and silica-coated
iron oxide nanoparticles is expected to be further increased due to
their reduced interaction with the body fluids. This study therefore
clearly underlines the importance of SiO2 coating towards
improving the uptake of Mag@SiO2 nanoparticles by PC3
prostate cancer cells, and improving the shelf life of MR contrast
agents. The magnetic-silica composite nanoparticles act as
promising T2 contrast agents offering a potentially viable option
as a commercial MR contrast agent. This is attributable to their
small size, high MR signal enhancement, relative biocompatibility,
longer shelf life, and highly modifiable silica surface chemistry
which will allow the adhesion of multiple molecular markers for
targeted MRI in the future. These characteristics of a T2 contrast
agent are highly desirable for magnetic resonance imaging
applications at the pre-clinical level and for later use clinically.
Materials and Methods
Ethics Statement
The breast tumor mice model was developed in-house, and all
the studies involving animals were pre-approved by institutional
animal ethics committee.
Materials
All chemicals were purchased from Sigma-Aldrich and used as
received without further modification. The prostate cancer cells
(PC3 cell line) were purchased from American Type Culture
Collection (ATCC). CellTiter 96 Aqueous One Solution Cell
Proliferation Assay (Promega) kit was purchased from Promega
Corporation.
Synthesis of iron oxide nanoparticles
Quasi-cubic iron oxide nanoparticles (referred as ‘Mag’) were
synthesized using a two step process significantly modified from Park
et al, thus leading to controlled large-scale synthesis [52]. During
synthesis, an iron oleate complex was first formed by dissolving 5.4 g
of iron chloride and 18.25 g of sodium oleate in a solution comprised
of 40 mL ethanol, 30 mL distilled water and 70 mL hexane. Once
homogenized, the solution was refluxed at 70uC for 4 h, followed by
separation of the upper organic layer using a separatory funnel,
w a s h i n ga n de v a p o r a t i n go f fh e x a n e ,t h e r e b yl e a v i n gaw a x yi r o n
oleate complex. The iron oxide nanocrystals were formed by
dissolving 9.0 g of the iron oleate complex in 1.425 g of oleic acid
and 63.3 mL of 1-octadecene, followed by reflux under nitrogen until
it reached 320uC, at which point the temperature was held for
30 min and then allowed to cool to room temperature. 250 mL of
ethanol was then added to the solution and the magnetite particles
were separated via centrifugation, followed by three washing cycles
with ethanol. Notably, by designing this protocol, scale up of at least
up to 10 g magnetic nanoparticles per reaction could be easily
achieved under laboratory conditions.
Figure 6. Evaluation of Mag@SiO2 nanoparticles as a T2 MR contrast agent is shown in the form of % signal enhancement with
increasing concentration of Fe using a 3 Tesla MR scanner. Panel A shows the studies performed in phantoms for particles in suspension,
while panel B shows the similar studies in PC3 human prostate cancer cells after nanoparticles uptake for 24 h. Corresponding T2-weighted MR
images of different samples, showing the image darkening effect with increasing Fe concentration are also shown under each bar.
doi:10.1371/journal.pone.0021857.g006
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nanoparticles
Silica-coated iron oxide nanoparticles (Mag@SiO2) were
prepared using a method significantly modified from Fang et al
and Morel et al [53–54], wherein controlled hydrolysis of silica
precursor in the presence of magnetite nanoparticles was
performed. In our approach, pre-formed magnetic particles were
used as nucleating sites for subsequent hydrolysis of silica
precursor around them. Briefly, 1 mg of iron oxide nanoparticles
prepared in the previous step were sonicated in a solution
consisting 15 mL ethanol and 2 mL deionized water (MilliQ).
1 mL of ammonia (25% solution) was added to the above solution
while immersed in a sonicator programmed to switch on for 1 min
in every 10 min. Further, an overhead stirrer was additionally
used to mix the solution while 4 mL of 1:60 (tetraethyl
orthosilicate:ethanol) was added at the rate of 0.4 mL/h using a
syringe pump, and the solution was allowed to stir at room
temperature for 12 h. The silica coated iron oxide nanoparticles
were centrifuged, washed three times with ethanol and redispersed
in MilliQ water.
Materials characterisation
The morphology and size of Mag and Mag@SiO2 nanopar-
ticles was characterized using JEOL 2010 high resolution
transmission electron (HRTEM) microscope operated at an
accelerating voltage of 200 kV. Samples for HRTEM measure-
ments were prepared by drop casting particles on to a carbon-
coated copper grid, followed by air drying. The crystallography of
the nanomaterial powders was obtained on a Bruker D8
ADVANCE X-ray diffractometer using Cu Ka radiation. For
magnetic measurements, a superconducting quantum interface
device based magnetometer (Quantum Design MPMS-XL5) was
used. The iron content of the nanoparticle solutions used for in vitro
and in vivo studies was ascertained on a Varian AA280FS Fast
Sequential Atomic Absorption Spectrometer (AAS) after digestion
of particles overnight in nitric acid.
In vitro cell studies and cytotoxicity assays
Human prostate cancer cells (PC3 cell line) were routinely
cultured at 37uC in a humidified atmosphere with 5% CO2 using
RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS), 1% penicillin, 1% streptomycin/penicillin and 1 mM L-
glutamine. For sub-culturing, PC3 prostate cancer cells were
detached by washing with phosphate buffered saline (PBS) and
incubating with trypsin-EDTA solution (0.25% trypsin, 1 mM
EDTA) for 5 min at 37uC, followed by washing and incubation
with supplemented RPMI 1641 medium. For cell uptake, the cells
were first seeded in 24-well polystyrene dishes for 24 h, followed
by incubation with Mag and Mag@SiO2 nanoparticles for 24 h at
37uC in complete cell media, and subsequent three times washing
of cells with PBS, before imaging under an inverted microscope.
For cytotoxicity assays, the viability of PC3 prostate cancer cells
exposed to Mag@SiO2 nanoparticles in the absence of cell growth
medium was determined. A CellTiter 96 AQueous One Solution
Cell Proliferation Assay (Promega) kit containing the tetrazolium
Figure 7. T2-weighted MR images of nude mice with breast tumor obtained (A) before and (B) after injection of MR contrast agent,
obtained using a 3 Tesla MR scanner. Mouse 2 was injected with Mag@SiO2 nanoparticles as T2 contrast agent, while Mouse 1 was injected with
saline as a control. Tumor sites in the control (mouse 1) and in the treated mouse (mouse 2) have been labelled as blue and red circles respectively.
Panels C and D show the higher magnification transverse section images of tumor site corresponding to Panels A and B respectively, wherein tumor
region injected with MR contrast agent has been highlighted using white circles.
doi:10.1371/journal.pone.0021857.g007
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nyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), was used to monitor
cell viability according to the manufacturer’s protocols. MTS color
change was monitored using a plate reader at 490 nm, and cell
viability data was plotted by considering the viability for the
untreated cells as 100%. Experiments were performed in
triplicates, and error bars represent standard experimental errors.
Magnetic resonance imaging (MRI) studies
MRI studies were performed for nanoparticle solutions stored in
phantoms, in PC3 prostate cancer cells after nanoparticle uptake,
and in a mouse model with breast cancer. For phantom MRI
studies, phantoms were prepared in Eppendorf tubes with
Mag@SiO2 nanoparticles at three different Fe concentrations
(0.18 mM, 0.9 mM, 1.79 mM) and a saline solution without any
nanoparticles was used as a control. For in vitro MRI studies, PC3
cancer cells were cultured using the above protocol in 24 well
polystyrene plates, and incubated for 24 h with Mag and
Mag@SiO2 nanoparticles at three different concentrations
(0.18 mM, 0.9 mM, 1.79 mM) and a control with cells but no
nanoparticles. MRI measurements for phantoms and PC3 cells
were performed with a clinical 3.0 Tesla Clinical Siemens Trio
MRI scanner using a 12-channel head coil and the following
parameters: T2-weighted imaging, gradient echo sequence,
multiple echo time (TE) ranging from 0.99–100 ms, repetition
time (TR)=2000 ms, matrix 1286128, slice thickness of 3 mm.
Relaxation rates (R2) were determined by using a single echo
sequence (SE) with a constant TR of 2000 ms and multiple TE
ranging from 0.99–100 ms. The signal was plotted as a function of
echo time and fitted to obtain the R2 values. The R2 values of the
Mag@SiO2 in phantoms and PC3 cells were determined by
plotting the relaxivity at a TE of 10.86 ms, as a function of molar
iron concentration in respective samples, and extracting the T2
value from the slope by linear regression of data points obtained at
lower Fe concentration values. Only lower Fe concentrations were
used to determine the T2 values, predominantly because with
increasing Fe concentrations above a particular threshold, the MR
signals tend to loose their linearity. For the in vitro MRI
measurements in phantoms and PC3 cells, enhancement of the
R2 signal within the PC3 cells was calculated by: DR2/
R2control*100. For in vivo MRI experiments, breast tumor
bearing mice were developed in-house, anaesthetised with
ketamine (80 mg per kg body weight) and xylazine (5 mg per kg
body weight), and placed within the 12-channel head coil. Images
were acquired before and after injection of 100 mL of Mag@SiO2
particles suspension of 100 mg/mL concentration in saline locally
at the tumor site. A T2-weighted spin echo sequence was acquired
with TE/TR of 60/2000 ms, a slice thickness of 3 mm and a
128x128 matrix. Data analysis was performed manually by placing
ROIs in tumor and tissue areas on the images.
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